Testing JL19001 for Advanced Cancers and Lymphoma
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This is an early-stage study testing a new drug called JL19001, alone or combined with standard treatments, for people with advanced solid tumors (like melanoma, lung cancer, or kidney cancer) or relapsed/refractory B-cell lymphoma who have exhausted standard options. The trial aims to find the safest dose and understand how well the drug works.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 18 or older
- Diagnosed with advanced solid tumor or B-cell non-Hodgkin lymphoma that has progressed despite at least 1–2 prior treatment lines (varies by cancer type); prior treatments often must include specific drugs like checkpoint inhibitors or targeted therapies depending on your cancer
- At least one measurable tumor visible on imaging scans
- Good enough overall health (ECOG performance status 0–1: able to care for yourself with minimal assistance)
- Normal or near-normal blood counts, liver and kidney function within the past 2 weeks
- No active brain metastases, serious heart problems, active infections, or recent major surgery
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This is an early-stage trial testing a new cancer treatment called JLM019 in patients with advanced solid tumors or lymphomas that haven't responded to other treatments. The study aims to find the right dose and see how well the drug works and how patients tolerate it.
This trial tests two new drugs, JS212 and JS213, alone or together, for people with certain advanced cancers that have stopped responding to standard treatments. The goal is to see if these drugs can shrink tumors or slow cancer growth.
This trial tests a new drug, JBZ-001, to see how safe it is for people with advanced solid tumors or certain types of lymphoma that have not improved with standard treatments. It's a first-in-human study, so participants will help doctors learn about the drug's side effects and the right dose.
This study tests an experimental drug (LNF1901) for people with advanced cancers that haven't responded to standard treatments. The goal is to see if it is safe and how well it works, and it might help control the cancer or shrink tumors.
This trial tests a new drug called JL19001, given alone or with BCG (a standard bladder cancer treatment), for people with high-risk bladder cancer that hasn't spread into the bladder muscle. The goal is to see if it can help prevent the cancer from coming back or getting worse.
This Phase 1 trial tests NBL-020, an injected medicine, in adults with advanced solid cancers (and possibly some skin T-cell lymphoma) to see how it works and how safe it is. You may be considered if standard treatment has stopped working or isn’t tolerated and if you can provide recent tumor tissue for lab testing.
Hear when a new Solid Tumor Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.